Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amgen (AMGN)

Amgen CFO Peter Griffith to retire; Thomas Dittrich named successor effective Sept. 1

Neutral Impact 4 of 5 leadership Written later

Amgen said Chief Financial Officer Peter Griffith will retire, with his CFO role ending August 31, 2026. Thomas Dittrich, former CFO of Galderma Group AG, will join as executive vice president on July 1, 2026 and become CFO on September 1, 2026, reporting to Chairman and CEO Robert A. Bradway. A change in the top finance role is significant for shareholders, and the filing lists Dittrich's pay and retention terms in Swiss francs.

Key points

  • Peter Griffith's CFO role ends August 31, 2026; he stays as a non-executive executive vice president from September 1, 2026 to January 31, 2027.
  • Thomas Dittrich, age 62, starts as executive vice president on July 1, 2026 and becomes CFO on September 1, 2026.
  • Dittrich's annual base salary is CHF 1,070,000, with a 100% target bonus opportunity.
  • Dittrich receives a one-time, two-year retention bonus of CHF 5,800,000, repayable pro rata if he leaves or is terminated for certain misconduct within two years.

The filing

CompanyAmgen (AMGN)
Form8-K, current report
Filed with the SECMay 19, 2026, 4:08 PM ET
Accession number0000318154-26-000097

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.